EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation

Clinical Cancer Research

Volumn 15, Issue 15, 2009, Pages 4904-4914

  Sun, Hui Lung ^a,b   Tsai, An Chi ^a   Pan, Shiow Lin ^a   Ding, Qingqing ^b   Yamaguchi, Hirohito ^b   Lin, Chun Nan ^c   Hung, Mien Chie ^b,d,e   Teng, Che Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e ASIA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3,6 BIS(2,3 EPOXYPROPOXY)XANTHONE; BIM PROTEIN; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN BAX; PROTEIN MCL 1; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CYCLE; CELL VIABILITY; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; UBIQUITINATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EPOXY COMPOUNDS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUTATHIONE; HUMANS; MICE; MICE, NUDE; MITOCHONDRIA; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-BCL-2; UMBILICAL VEINS; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68049133167     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0269     Document Type: Article

References (43)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18
2. Ou-Yang F, Lan KL, Chen CT, et al. Endostatincytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer Res 2006;66:378-384 (Pubitemid 43166045)
3. Duval H, Harris M, Li J, Johnson N, Print C. New insights into thefu nction and regulation of endothelial cell apoptosis. Angiogenesis 2003; 6:171-183 (Pubitemid 38506662)
4. Dimmeler S, Zeiher AM. Endothelial cell apoptosis in angiogenesis and vessel regression. Circ Res 2000;87:434-439 (Pubitemid 30736734)
5. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res 2000;60:1878-1886 (Pubitemid 30207647)
6. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436
7. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003;13:159-167
8. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603. (Pubitemid 39025054)
9. Moran LK, Gutteridge JM, Quinlan GJ. Thiols in cellular redox signalling and control. Curr Med Chem 2001;8:763-772
10. McEligot AJ, Yang S, Meyskens FL. Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. Annu Rev Nutr 2005;25:261-295 (Pubitemid 41209003)
11. Pinto MM, Sousa ME, Nascimento MS. Xanthone derivatives: new insights in biological activities. Curr Med Chem 2005;12:2517-2538 (Pubitemid 41408417)
12. McKeage MJ, Von PJ, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-2012
13. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-148
14. Lin CN, Liou SJ, Lee TH, Chuang YC, Won SJ. Xanthone derivatives as potential anti-cancer drugs. J Pharm Pharmacol 1996;48:539-544
15. Liu HS, Lin CN, Won SJ. Antitumor effect of 2,6-di(2,3-epoxypropoxy) xanthone on tumor cell line. Anticancer Res 1997;17:1107-1114
16. Ding Q, HeX, Hsu JM, et al. Degradation of Mcl-1 by β-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007;27:4006-4017 (Pubitemid 47010998)
17. Peng CY, Pan SL, Lee KH, Bastow KF, Teng CM. Molecular mechanism of the inhibitory effect of KS-5 on bFGF-induced angiogenesis in vitro and in vivo. Cancer Lett 2008;263:114-121
18. Dong LF, Swettenham E, Eliasson J, et al. Vitamin E analogues inhibit angiogenesis by selectivein duction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res 2007;67:11906-11913
19. HuangYT,HuangDM,GuhJH,Che n IL,TzengCC, Teng CM. CIL-102 interacts with microtubule polymerization and causes mitotic arrest following apoptosis in thehuman prostatecance r PC-3 cell line. J Biol Chem 2005;280:2771-2779
20. Chen WY, Wu CC, Lan YH, Chang FR, Teng CM, Wu YC. Goniothalamin induces cell cycle-specific apoptosis by modulating there dox status in MDA-MB-231 cells. Eur J Pharmacol 2005;522: 20-29
21. SunHL, Liu YN,HuangYT, et al.YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia. Oncogene 2007;26:3941-3951
22. Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN, Wang HG. EpothiloneB analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res 2002; 62:466-471 (Pubitemid 34106420)
23. Shtivelband MI, Juneja HS, Lee S, Wu KK. Aspirin and salicylateinhibit colon cancer medium- and VEGF-induced endothelial tubef ormation: correlation with suppression of cyclooxygenase-2 expression. J Thromb Haemost 2003;1:2225-2233
24. Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005;17:525-535 (Pubitemid 40269117)
25. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 1997;139:1281-1292 (Pubitemid 27523214)
26. Osband AJ, Deitch EA, Lu Q, et al. The role of oxidant-mediated pathways in the cytotoxicity of endothelial cells exposed to mesenteric lymph from rats subjected to trauma-hemorrhagic shock. Shock 2003;20:269-273
27. Hammond CL, Lee TK, Ballatori N. Novel roles for glutathionei n genee xpression, cell death, and membrane transport of organic solutes. J Hepatol 2001;34:946-954 (Pubitemid 32595199)
28. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004;23:5301-5315
29. Li QM, Tep C, Yune TY, et al. Opposite regulation of oligodendrocyte apoptosis by JNK3 and Pin1 after spinal cord injury. J Neurosci 2007;27: 8395-8404 (Pubitemid 47219616)
30. Ding Q, Huo L, Yang JY, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 2008;68:6109-6117
31. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of themul tikinasei nhibitor BAY 43- 9006. Oncogene 2005;24:6861-6869 (Pubitemid 41509409)
32. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-2049
33. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathioneme tabolism and its implications for health. J Nutr 2004;134:489-492 (Pubitemid 38298485)
34. Mehdi MZ, Azar ZM, Srivastava AK. Role of receptor and nonreceptor protein tyrosine kinases in H2O2-induced PKB and ERK1/2 signaling. Cell Biochem Biophys 2007;47:1-10.
35. Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007;19:488-496 (Pubitemid 47487452)
36. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-399
37. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3- only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403. (Pubitemid 40193310)
38. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-791 (Pubitemid 46192219)
39. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizesMCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 2007;104: 19512-19517
40. Mikula M, Schreiber M, Husak Z, et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J 2001;20: 1952-1962 (Pubitemid 32397397)
41. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006;33: 392-406. (Pubitemid 44142735)
42. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 2007; 356:185-187
43. Meng XW, Lee SH, Dai H, et al. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 2007;282:29831-29846 (Pubitemid 350035287)